DUBLIN, July 24, 2020 /PRNewswire/ — The “Glioblastoma Multiforme (GBM) – Market Insights, Epidemiology and Market Forecast- 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The report delivers an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glioblastoma Multiforme (GBM) market size from 2017 to 2030. The report also covers current Glioblastoma Multiforme (GBM) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Glioblastoma Multiforme (GBM), Gender-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Type-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Age-specific Diagnosed Incidence of Glioblastoma Multiforme (GBM), Diagnosed Incident Population based on Primary Site of Glioblastoma Multiforme (GBM) Tumour and Diagnosed Incident Population based on Histologic Classification of Glioblastoma Multiforme (GBM) Tumor in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
- The total diagnosed incident population of Glioblastoma Multiforme in the 7 major markets was estimated to be 28,259 in 2017. In case of Glioblastoma Multiforme patients in the United States, the diagnosed cases were 14,666 in 2017.
- The total diagnosed incident cases of Glioblastoma Multiforme patients were found to be maximum in males as compared to females in the 7 MM during the study period of 2017-2030.
- In the EU5 countries, the diagnosed incident population of Glioblastoma Multiforme was found to be maximum in Germany with 2,876 cases followed by France with 2,683 cases in 2017. While, Spain accounted for the lowest diagnosed incident population of 1,403 in 2017.
- As per the analysis, Japan had 1,899 diagnosed incident cases of Glioblastoma Multiforme in 2017.
The drug chapter segment of the Glioblastoma Multiforme (GBM) report encloses the detailed analysis of Glioblastoma Multiforme (GBM) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Glioblastoma Multiforme (GBM) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps in reducing the activity of VEGF and regressing the vascularization of tumors, which normalizes the tumor vasculature and inhibits the formation of new tumor vasculature, thereby preventing the tumor growth. VEGF is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States. In September 2014, Genentech reclassified the drug under Specialty drugs, only to be available through specialty pharmacies (under FDA’s Risk Evaluation and Mitigation Strategy (REMS) program).
Avastin is indicated for the treatment of glioblastoma with progressive disease in adult patients following prior therapy as a single agent. The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate, wherein no data demonstrate any improvement in disease-related symptoms or increased survival with Avastin.
The active pharmaceutical ingredient in Temodar/Temodal, is an imidazotetrazine derivative of the alkylating agent dacarbazine. Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for glioblastoma. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. Temozolomide targets selectively tumoral tissues; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity, and it is eliminated rapidly. Temodar/Temodal was initially commercialized by Merck in the different countries, whereas Baxter Oncology was responsible for the manufacture of Temodar injection. However, due to patent expiry, the market holds the generic version of the drug. Recently, the gel formulation of Temozolomide has also been approved by Double Bond Pharmaceuticals.
- Ofranergene obadenovec (VB-111): VBL Therapeutics
- Trans Sodium Crocetinate: Diffusion Pharmaceuticals
- Regorafenib: Bayer
- Durvalumab (MEDI4736): MedImmune
- Tasadenoturev (DNX-2401): DNAtrix
- ONC201: Oncoceutics
- Selinexor (KPT-330): Karyopharm Therapeutics
- Paxalisib (GDC-0084): Kazia Therapeutics
- AV-GBM-1: Aivita Biomedical
- MDNA55: Medicenna Therapeutics
In April 2005, the FDA approved a new indication for Temodar capsules (temozolomide) for concurrent use with radiotherapy for the treatment of adults with newly diagnosed GBM and as maintenance therapy after radiotherapy. Inaddition, in December 2017, the FDA granted full approval of bevacizumab (Avastin) for the treatment of adults with recurrent glioblastoma that has progressed following prior therapy. In case of European and Japanese market, only Temodar has been approved by the EMA and MHLW respectively, for the treatment of patients with GBM.
Glioblastoma Multiforme pipeline is robust and possesses multiple potential drugs in late and mid-stage developments, which is yet to be launched. The pipeline involves drugs with a varied mechanism of action along with different routes of administration, ranging from oral, intravenous, intratumoral, subcutaneous, etc. It is interesting to note that the emerging market of GBM includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.
The potential candidates with promising results in late- or phase III stage of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), and Regorafenib (Bayer).
- The market size of GBM in the seven major markets was estimated to be USD 1,005 Million in 2017.
- The United States accounts for the largest market size of GBM throughout the study period of 2017-2030, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be USD 629 Million in 2017.
- Among the EU5 countries, Germany had the highest market size with USD 73 Million in 2017, while Spain had the lowest market size with USD 35 Million.
- Japan accounted for the second highest market size in the 7 MM during the forecast period of 2020-2030, which was estimated to be USD 82 Million in 2017.
This section focusses on the rate of uptake of the potential drugs recently launched in the Glioblastoma Multiforme (GBM) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Glioblastoma Multiforme (GBM) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Glioblastoma Multiforme (GBM) emerging therapies.
Competitive Intelligence Analysis
The publisher performs competitive and market Intelligence analysis of the Glioblastoma Multiforme (GBM) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Glioblastoma Multiforme (GBM), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
- Comprehensive insight has been provided into the Glioblastoma Multiforme (GBM) epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Glioblastoma Multiforme (GBM) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of Glioblastoma Multiforme (GBM) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Glioblastoma Multiforme (GBM) market.
- In the coming years, Glioblastoma Multiforme (GBM) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Glioblastoma Multiforme (GBM) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- The publisher has analysed type-specific data of GBM according to which there are two main types of Glioblasoma: Primary (de novo) and Secondary Glioblastoma, where the majority of cases (>90%) are primary glioblastomas that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion.
- Diagnosed incidence according to histological classification of Glioblastoma Multiforme tumor was also assessed, which suggests that the conventional GBM type is more prevalent than giant cell GBM (GC-GBM), and gliosarcoma (GS).
- In addition, gender-specific incidence of Glioblastoma Multiforme was also assessed. As per the analysis, GBm is more prevalent in males than in females.
- The epidemiology segmentation also encompasses diagnosed incident population according to primary site of glioblastoma. As per the estimates, it has been found that the primary site of GBM included maximum cases at parietal site, while minimum number of cases were found in unknown and other sites. This trend is clearly evident across all the 7MM countries for the study period 2017-2030.
- The report also encompasses another major segment, i.e., Age-specific Diagnosed Incident Population of Glioblstoma Multiforme (GBM), wherein various age groups have been considered, such as < 18, 18-34, 35-64, 65-74 and 75+. It has been found that GBM incidence increases with age peaking at 75-84 years and drops after 85 years.
- Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of GBM. The market is expected to witness a significant positive shift owing to the positive outcomes of the several products during the developmental stage by key players such as Bayer, Diffusion Pharmaceuticals, VBL Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Oncoceutics, KaryoPharma, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Immunomic Therapeutics and Inovio Pharmaceuticals.
- VBL Therapeutics
- Diffusion Pharmaceuticals
- Karyopharm Therapeutics
- Kazia Therapeutics
- Aivita Biomedical
- Medicenna Therapeutics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/l5xdlz
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets